Penumbra Stock

Penumbra EBIT per Employee

The EBIT per Employee of Penumbra (PEN) as of Aug 12, 2026 is 70,092.22 USD. In the previous year, EBIT per Employee was 3,436.67 USD — a change of 1,939.54% (higher).

EBIT per Employee

70,092.22USD

YoY

1,939.54%

Last updated:

EBIT per Employee of Penumbra is 2026 70,092.22 USD. EBIT per Employee of Penumbra was 2025 3,436.67 USD. It decreases by 1,939.54% higher compared to the previous year.
Access this data via the Eulerpool API

Penumbra Stock analysis

What does Penumbra do? Penumbra Inc is an American company specializing in medical technology. It was founded in 2004 and is headquartered in Alameda, California. The company has branches and subsidiaries worldwide. It offers various products for the treatment of strokes, aneurysms, vascular injuries, and other medical conditions. The history of Penumbra Inc began with the founder and CEO Adam Elsesser's vision to develop innovative technologies to help patients with challenging medical conditions. The company started with just one product, the Penumbra 3D Coiling Technology, which is used for the treatment of brain aneurysms. Penumbra Inc's business model is based on the development and marketing of innovative medical devices and technologies to assist surgeons and specialists in treating their patients better. The company conducts intensive research and development to create new products that meet market demand. Penumbra Inc is divided into different divisions to offer a comprehensive range of medical tools and devices to its customers. The main divisions of the company are Neuro, Vascular, and Oncology. Under the Neuro division, Penumbra Inc offers a wide range of devices and technologies for the treatment of strokes and trauma. This includes the Penumbra Coil 400, used for treating intracranial aneurysms, and the Penumbra Jet 7 Reperfusion Catheter, an innovative technology for restoring blood flow in stroke patients' brains. The Vascular division of Penumbra Inc provides devices for the treatment of vascular diseases, such as endovascular repairs of aortic aneurysms. This division utilizes the innovative Penumbra SMART Coil technology, which provides improved handling and safety. The Oncology division of Penumbra Inc focuses on developing technologies to enhance healthcare for cancer patients. This includes innovative drug delivery devices, such as the Penumbra System used in brachytherapy. Penumbra Inc is a leading provider of medical devices and technologies used in the treatment of complex medical conditions. Over the past decade, the company has established its reputation in the industry. Continuous investment in research and development and a focus on patient and medical professionals' needs have solidified Penumbra Inc's success in the international market. Penumbra is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Penumbra stock

EBIT per Employee of Penumbra is 70,092.22 USD in 2026.

EBIT per Employee of Penumbra changed from 3,436.67 USD to 70,092.22 USD, representing a 1,939.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Penumbra since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Penumbra historically and in real time.

Access this data via the Eulerpool API

Workforce — Penumbra

All Key Metrics — Penumbra